Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

The potential of preoperative dynamic electromyography in guiding targeted surgical procedures for elbow spasticity
Wang, Zheng , Lunasin, Ray M. , Hoffman, E. Matthew , Rhee, Peter C. , Hoffman, Ernest M., Kaufman, Kenton R , Lieber, Richard L. , Kaufman, Kenton R.

Mayo Clinic

Journal of Hand Surgery (European Volume) | February 28, 2025 | Volume: 50 | Issue: 11 | Pages: 1534-1537

10.1177/17531934251323078 | PMID 40017304 Get It

Six patients treated by hyperselective neurectomy were assessed using preoperative dynamic electromyography and intraoperative force measurements. Patients with lower preoperative biceps dynamic electromyography activation had significantly reduced force production at operation, suggesting that these findings could guide and improve procedure selection. Level of evidence: IV
Biomechanical modeling and assessment of patient positioning to facilitate spinal deformity instrumentation
Wang, Xiaoyu , Imbleau-Chagnon, Guillaume, Caouette, Christiane , Aubin, Carl‐Éric , Larson, A. Noelle

Mayo Clinic

Computer Methods in Biomechanics and Biomedical Engineering | February 26, 2025 | Volume: 29 | Issue: 9 | Pages: 2020-2029

10.1080/10255842.2025.2470796 | PMID 40007414 Get It

Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture
DeSapri, Kristi Tough, Kostenuik, Paul, Clarke, B.L. , Kostenuik, Paul J. , Wang, Yamei , Mitlak, Bruce

Mayo Clinic

Menopause | February 25, 2025 | Volume: 32 | Issue: 5 | Pages: 388-395

10.1097/gme.0000000000002516 | PMID 39999474 Get It

Objective: This post hoc analysis evaluated the efficacy of abaloparatide treatment in a subgroup of postmenopausal women from the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE; NCT01343004) study who met high fracture risk criteria (defined in several professional society guidelines). Methods: Women from ACTIVE meeting ≥1 of the following fracture risk criteria were included: fracture within the past 12 months or prevalent vertebral fracture, baseline T score of <−3.0 at any site, very high fracture risk probability by FRAX (ie, 10-yr major osteoporotic fracture >30% or hip fracture >4.5%), or multiple prior fractures at baseline since age ≥45 years. Results: A total of 2,026 participants met ≥1 fracture risk criteria defined in clinical guidelines (abaloparatide, n = 664; placebo, n = 677; teriparatide, n = 685). New vertebral fracture risk was reduced in participants receiving abaloparatide (4 [0.72%]) and teriparatide (6 [0.99%]) versus placebo (28 [4.77%]; both P < 0.0001). Estimated Kaplan-Meier cumulative incidence of nonvertebral fracture was 3.0%, 5.3%, and 3.0% in the abaloparatide, placebo, and teriparatide groups, respectively; 4.0%, 9.0%, 4.3% for clinical fracture; 1.6%, 6.8%, 3.0% for major osteoporotic fractures; and 1.1%, 2.1%, 2.1% for wrist fracture. Abaloparatide was associated with bone mineral density gains from baseline at the lumbar spine, total hip, and femoral neck at all time points (6, 12, and 18 mo; P < 0.0001 for all). Common adverse events reported in participants treated with abaloparatide were hypercalciuria (11.5%), dizziness (11.0%), and arthralgia (8.9%). Conclusions: Abaloparatide reduced fracture incidence and increased bone mineral density in participants at highest fracture risk, consistent with the overall ACTIVE study.
pTDP-43 levels correlate with cell type–specific molecular alterations in the prefrontal cortex of C9orf72 ALS/FTD patients
Veire, Austin M. , Murray, Melissa E. , Tansey, Malú G. , Hu, Jian , Gearing, Marla , Glass, Jonathan D. , Corces, Victor G. , McEachin, Zachary T. , Murray, Melissa E , Tansey, Malú G , Glass, Jonathan D , Jin, Peng , Corces, Victor G , Wang, Hsiao‐Lin V. , Xiang, Jian‐Feng , Yuan, Chenyang , Gendron, Tania F.

Mayo Clinic

Proceedings of the National Academy of Sciences | February 25, 2025 | Volume: 122 | Issue: 9 | Pages: No page available

10.1073/pnas.2419818122 | PMID 39999167 Get It

Repeat expansions in the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis and familial frontotemporal dementia (ALS/FTD). To identify molecular defects that take place in the dorsolateral frontal cortex of patients with C9orf72 ALS/FTD, we compared healthy controls with C9orf72 ALS/FTD donor samples staged based on the levels of cortical phosphorylated TAR DNA binding protein (pTDP-43), a neuropathological hallmark of disease progression. We identified distinct molecular changes in different cell types that take place during FTD development. Loss of neurosurveillance microglia and activation of the complement cascade take place early, when pTDP-43 aggregates are absent or very low, and become more pronounced in late stages, suggesting an initial involvement of microglia in disease progression. Reduction of layer 2-3 cortical projection neurons with high expression of CUX2/LAMP5 also occurs early, and the reduction becomes more pronounced as pTDP-43 accumulates. Several unique features were observed only in samples with high levels of pTDP-43, including global alteration of chromatin accessibility in oligodendrocytes, microglia, and astrocytes; higher ratios of premature oligodendrocytes; increased levels of the noncoding RNA NEAT1 in astrocytes and neurons, and higher amount of phosphorylated ribosomal protein S6. Our findings reveal progressive functional changes in major cell types found in the prefrontal cortex of C9orf72 ALS/FTD patients that shed light on the mechanisms underlying the pathology of this disease.
A Novel Giant Magnetoresistance–Enabled Multiplex Polymerase Chain Reaction Assay for the Diagnosis of Invasive Fungal Infection
Vergidis, Paschalis , Ordaya, Eloy E. , Porter, Emma, Sweet, Hannah, Wang, Wei , Evans, Anton F. , Zhang, Chi , Young, Jo‐Anne H. , Liu, Xiaoying , Vergidis, Paschalis , Young, Jo-Anne H , Zhang, Chi

Mayo Clinic

Open Forum Infectious Diseases | February 25, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaf068 | PMID 40008305 Get It

Abstract Background Despite advances in clinical microbiology, the diagnosis of invasive fungal infections remains challenging. Giant magnetoresistance (GMR) is a novel technology that enables the detection of trace amounts of cell-free DNA (cfDNA). We evaluated a high-multiplex molecular diagnostic assay coupled with GMR-enabled lab-on-a-chip technology that can detect 18 different fungal species. Methods Analytical performance was evaluated in spiked plasma samples. After amplification, cfDNA was digested. Residual single-stranded DNA was flowed over a GMR sensor that was surface-coated with probes specific to different fungal species. After hybridization, magnetic beads bound to the probe complexes produced a GMR signal that was detected by the sensors. Clinical performance was determined using residual serum samples collected before the initiation of antifungal treatment from 20 patients with infection. Results The limit of detection of the assay ranged from 5 to 50 copies per polymerase chain reaction (PCR) reaction. Nonspecific signals were not observed in the spiked samples. Fungal cfDNA was detected in 80% of patients with invasive candidiasis (3/4 with candidemia, 5/6 with invasive candidiasis without candidemia), all 3 cases of invasive pulmonary aspergillosis, and all 3 cases of disseminated histoplasmosis. cfDNA was not detected in 2 patients with cryptococcosis (both had negative blood cultures) and 2 patients with Pneumocystis pneumonia. Conclusions We developed a novel GMR-enabled multiplex PCR assay detecting fungal pathogens that have been prioritized for public health action. Clinical sensitivity was highest in cases of presumed angioinvasion and dissemination. This technology has the potential for use in the clinical microbiology laboratory setting.
Abstract B034: The immune checkpoint molecule B7-H3 is a driver of tumor immune exclusion by mediating TGF-β activation
Lavoie, Roxane R. , Korleski, Jack , Kim, Yohan, Farrell, Ava, Harper, Kelly , Charbonneau, Martine , Frank, Igor, Gupta, Sounak , Cheville, John C. , Orme, Jacob J. , Boorjian, Stephen A. , Shah, P., Kwon, Eugene D., Lucien, Fabrice , Wootla, Bharath , Wang, Liguo , Dubois, Claire M. , Park, Sean S. , Dong, Haidong

Mayo Clinic

Cancer Immunology Research | February 23, 2025 | Volume: 13 | Issue: 2_Supplement | Pages: B034-B034

10.1158/2326-6074.io2025-b034 Get It

Abstract Addressing the limited responsiveness to immune checkpoint blockade (ICB) in human cancers remains a critical challenge. Efforts over the past two decades have primarily focused on enhancing CD8 T cell function and preventing their exhaustion. However, less attention has been given to understanding the molecular mechanisms that contribute to the immunosuppressive tumor microenvironment (TME), which impedes CD8 T cell infiltration and fosters ICB resistance. The TME in ICB-resistant tumors is characterized by Transforming Growth Factor beta (TGF-β) cytokine signaling, leading to a fibrotic extracellular matrix (ECM) and the accumulation of immunosuppressive fibroblasts and myeloid cells. These features hinder CD8 T cell penetration, thereby promoting immune escape. The immune checkpoint molecule B7-H3, overexpressed in ICB-resistant cancers, has been linked to impaired CD8 T cell infiltration and poor prognosis. However, the molecular mechanisms governing B7-H3 function remain poorly understood. We investigated the relationship between B7-H3 gene expression and ICB response using transcriptomic data from two randomized phase 3 trials (IMvigor010 and IMvigor210). Bulk RNAseq data, tissue staining, and spectral flow cytometry were used to characterize the TME composition of B7-H3 high and low tumors. Multi-omic profiling of tumor cell lines with manipulated B7-H3 expression was performed to identify downstream targets of B7-H3. Syngeneic mouse tumor models were used to assess the impact of B7-H3 on tumor growth and antitumor immunity. High B7-H3 expression was associated with shorter overall survival in both IMvigor010 (HR=0.48, 95% CI: 0.33-0.70, p&lt;0.0001) and IMvigor210 trials (HR=0.68, 95% CI: 0.51-0.92, p=0.01). In ICB-refractory cancers, B7-H3 expression correlated with high levels of fibroblasts, collagen deposits, and M2 macrophages. Gene set enrichment analysis revealed a positive association between B7-H3 and TGF-β signaling. Genetic deletion of B7-H3 in tumor cells reduced the surface expression of MMP14, a metalloprotease that activates TGF-β. Pan-cancer analysis identified MMP14 as the gene most correlated with B7-H3 (Pearson r=0.69, p&lt;0.0001). TGF-β activation was reduced by 70% in B7-H3 knockout cells compared to wild-type. Loss of B7-H3 led to MMP14 accumulation in lysosomes, resulting in its degradation. We generated a B7-H3 inhibitor, 5D10, which promotes MMP14 degradation and inhibits TGF-β activation. In humanized B7-H3 mouse models, 5D10 significantly reduced TGF-β activation, enhancing CD8 T cell infiltration and impairing tumor growth. Our research identifies B7-H3 as a driver of immune exclusion and ICB resistance. We describe a novel, receptor-independent mechanism where B7-H3 promotes TGF-β activation via stabilization of MMP14. Targeting B7-H3 represents a strategy to modulate the TME, transforming immune-excluded tumors into immune-inflamed states that may respond better to ICB. Citation Format: Fabrice Lucien, Roxane Lavoie, Jack Korleski, Yohan Kim, Bharath Wootla, Liguo Wang, Ava Farrell, Kelly Harper, Martine Charbonneau, Claire Dubois, Igor Frank, Sounak Gupta, John Cheville, Jacob Orme, Stephen Boorjian, Parash Shah, Eugene Kwon, Sean Park, Haidong Dong. The immune checkpoint molecule B7-H3 is a driver of tumor immune exclusion by mediating TGF-β activation [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr B034.
Artificial intelligence-enabled automated analysis of transmission electron micrographs to evaluate chemotherapy impact on mitochondrial morphology in triple negative breast cancer
Arriojas, Argenis , Baek, Mokryun L. , Berner, Mariah J. , Wang, Jiaqi, Duraisingh, Joseph, Zhurkevich, Alexander, Meyer, Matthew D. , Dobrolecki, Lacey E. , Lewis, Michael T. , Zarringhalam, Kourosh , Hinton, Antentor , Meyer, Matthew D , Dobrolecki, Lacey E , Lewis, Michael T , Zarringhalam, Kourosh , Wang, Jiaqi, Duraisingh, Joseph, Hinton, Antentor , Echeverria, Gloria Vittone

Mayo Clinic

No container title available | February 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.19.635300 | PMID 40027627 Get It

ABSTRACT Advancements in transmission electron microscopy (TEM) have enabled in-depth studies of biological specimens, offering new avenues to large-scale imaging experiments with subcellular resolution. Mitochondrial structure is of growing interest in cancer biology due to its crucial role in regulating the multi-faceted functions of mitochondria. We and others have established the crucial role of mitochondria in triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer with limited therapeutic options. Building upon our previous work demonstrating the functional role of mitochondrial structure dynamics in the metabolic adaptations and survival of chemotherapy-refractory TNBC cells, we sought to extend those findings to a large-scale analysis of transmission electron micrographs. Here we present a novel U-Net artificial intelligence (AI) model for automatic annotation and assessment of mitochondrial morphology and feature quantification. Our model is trained on 11,039 manually annotated mitochondria across 125 micrographs derived from a variety of orthotopic patient-derived xenograft (PDX) mouse model tumors and adherent cell cultures. The model achieves an F1 score of 0.85 on test micrographs at the pixel level. To validate the ability of our model to detect expected mitochondrial structural changes, we utilized micrographs from mouse primary skeletal muscle cells genetically modified to lack Dynamin-related protein 1 (Drp1). We subjected in vitro and in vivo TNBC models to conventional chemotherapy treatments commonly used for clinical management of TNBC, including doxorubicin, carboplatin, paclitaxel, and docetaxel (DTX). We found substantial within-sample heterogeneity of mitochondrial structure in both in vitro and in vivo TNBC models. In four of five PDX models, in vivo treatment with DTX elicited significant alteration in mitochondrial elongation and/or area. We went on to compare mammary tumors and matched lung metastases in a highly metastatic PDX model of TNBC, uncovering significant increase in mitochondrial elongation in metastatic lesions compared to their matched primary mammary tumor. The successful application of our AI model to capture mitochondrial structure marks a step forward in high-throughput analysis of mitochondrial structures, enhancing our understanding of how morphological changes may relate to chemotherapy efficacy and mechanism of action. Our large, manually curated electron micrograph dataset - now publicly available - serves as a unique resource for developing, benchmarking, and applying computational models, while further advancing investigations into mitochondrial morphology and its impact on breast cancer biology. This study provides proof of concept that mitochondrial structural remodeling is an additional layer of cellular reprogramming accompanying therapeutic resistance TNBC that merits further investigation.
Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes
Krittanawong, Chayakrit , Wang, Zhen , Qadeer, Yusuf Kamran , Moras, Errol , Jneid, Hani , Sharma, Samin K. , Ahuja, Tania , Virk, Hafeez Ul Hassan , Alam, Mahboob

Mayo Clinic

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine | February 21, 2025 | Volume: 24 | Issue: 1 | Pages: e0372

10.1097/hpc.0000000000000372 | PMID 39133562 Get It

Introduction: Data on outcomes between unfractionated heparin and bivalirudin anticoagulation during percutaneous coronary intervention (PCI) in acute coronary syndromes remain inconclusive. We aimed to systematically analyze PCI outcomes by comparing unfractionated heparin and bivalirudin. Methods: We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception in 1966 through January 2024 for studies evaluating PCI outcomes comparing unfractionated heparin and bivalirudin. Two investigators independently reviewed the data. Conflicts were resolved through consensus. Random-effects meta-analyses were used. Results: A total of 10 prospective trials were identified that enrolled 42,253 individuals who presented with an acute coronary syndrome. Our analysis found that heparin when compared to bivalirudin was associated with an increased risk of trial-based definition of major bleeding [relative risk (RR): 1.68, 95% confidence interval (CI): 1.29–2.20], nonaccess site complications (RR: 4.6, 95% CI: 1.75–12.09), thrombolysis in myocardial infarction major bleeding (RR: 1.70, 95% CI: 1.20–2.41), major bleeding risks (RR: 1.87, 95% CI: 1.49–2.36), cardiovascular disease death (RR: 1.26, 95% CI: 1.02–1.57), and thrombocytopenia (RR: 1.67, 95% CI: 1.07–2.62). There were no statistically significant differences between heparin and bivalirudin for all-cause mortality, major adverse cardiovascular event, stroke, reinfarction, target vessel revascularization, and acute or stent thrombosis. Conclusions: The present meta-analysis demonstrates bivalirudin reduces major bleeding when used for anticoagulation during PCI in patients with acute coronary syndromes and is not associated with an increased risk of stent thrombosis or major adverse cardiovascular event.
Setting higher standards for migraine prevention: A position statement of the International Headache Society
Sacco, Simona , Diener, Hans‐Christoph , Haghdoost, Faraidoon , Lee, Mi Ji , Monteith, Teshamae , Jenkins, Bronwyn , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Ornello, Raffaele , Puledda, Francesca , Sakai, Fumihiko , Tassorelli, Cristina , Diener, Hans-Christoph , Haghdoost, Faraidoon , Lee, Mi Ji , Monteith, Teshamae S , Rozen, Todd D. , Pozo-Rosich, Patricia , Ornello, Raffaele , Puledda, Francesca , Schwedt, Todd J , Wang, Shuu-Jiun , Ahmed, Fayyaz , Tassorelli, Cristina , Sacco, Simona , Ashina, Messoud , Schwedt, Todd J. , Terwindt, Gisela M. , Vaghi, Gloria , Wang, Shuu‐Jiun , Ahmed, Fayyaz

Mayo Clinic

Cephalalgia | February 21, 2025 | Volume: 45 | Issue: 2 | Pages: No page available

10.1177/03331024251320608 | PMID 39980456 Get It

Migraine is one of the most prevalent and disabling neurological diseases, significantly affecting quality of life and productivity, as well as contributing to substantial societal costs. Recent innovations, including calcitonin gene-related peptide (CGRP) pathway inhibitors and onabotulinumtoxinA, have transformed migraine prevention by offering high efficacy and excellent tolerability, thus improving adherence. Clinical trials and real-world studies show that significant reductions in migraine frequency and, in some cases, complete migraine freedom is achievable. In this Position Statement, we advocate for raising the standards of migraine prevention by setting ambitious treatment goals aimed at optimal outcomes, such as migraine freedom or very low number of days with migraine or moderate/severe headache. We emphasize the importance of addressing residual migraine burden, highlighting that achieving a ≥50% reduction in monthly migraine days, although often considered a successful response, may not fully restore quality of life. Relying solely on percentage-based improvements can obscure the persisting impact of residual burden. This Position Statement does not want to change the standards for clinical trials but aims primarily at real-world clinical practice and proposes a shift from percentage-based measures of success to absolute goals while on treatment. We outline a framework that categorizes outcomes into four tiers: migraine freedom (no days with migraine or moderate-to-severe headache), optimal control (less than four days with migraine or moderate-to-severe headache), modest control (four to six days with migraine or moderate-to-severe headache) and insufficient control (more than days with migraine or moderate-to-severe headache). Focusing on residual burden while on treatment aims to further improve patient quality of life and drive innovation in preventive therapies and non-pharmacological approaches. By advocating for higher standards, this Position Statement, is not aimed primarily to drive reimbursement policies for migraine preventive treatments, but seeks to inspire clinicians, researchers and policymakers to prioritize ambitious goals in migraine prevention, ultimately enhancing patient outcomes and reducing the broader societal and economic impact of this debilitating condition.
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, Cindy X. , Hribar, Michelle R. , Swaminathan, Swarup S. , Flowers, Alexis , Brown, Eric N. , Chen, John J. , Chen, Aiyin , Wang, Sophia Y. , Ehrlich, Joshua R. , Armbrust, Karen R. , Alshammari, Thamir , Swerdel, Joel N. , Suchard, Marc A. , Falconer, Thomas , DuVall, Scott L. , Viernes, Benjamin , O’Brien, William J. , Martin, Benjamin , Westlund, Erik , Mathioudakis, Nestoras , Fan, Ruochong, Stocking, Jacqueline C. , Takkouche, Sahar , Humes, Izabelle, McCoy, David , Adibuzzaman, Mohammad, Areaux, Raymond G. , Rojas‐Carabali, William , Brash, James T., Lee, David A. , Mawn, Louise A. , Agrawal, Rupesh, Morgan‐Cooper, Hannah, Desai, Priya , Ryan, Patrick , Barkmeier, Andrew, Chen, John J , Mathioudakis, Nestoras N , Stocking, Jacqueline C , Lee, Cecilia S , Baxter, Sally L. , Goetz, Kerry , Toy, Brian C. , Xu, Benjamin Yixing , Leng, Theodore , Barkmeier, Andrew J. , Boland, Michael V. , Dorr, David A , Boyce, Danielle M. , Schuemie, Martijn J. , Bu, Fan , Sena, Anthony G. , Hripcsak, George , Nishimura, Akihiko, Nagy, Paul G. , Matheny, Michael E. , Zhang, Linying , Martin, Benjamin, Fan, Ruochong, Wilcox, Adam B , Lai, Albert M. , Lee, Lok Hin , Xie, Yangyiran , Weiskopf, Nicole G. , Desai, Priya

Mayo Clinic

JAMA Ophthalmology | February 20, 2025 | Volume: 143 | Issue: 4 | Pages: 304

10.1001/jamaophthalmol.2024.6555 | PMID 39976940 Get It

Importance Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D). Objective To investigate the potential association between semaglutide and NAION in the Observational Health Data Sciences and Informatics (OHDSI) network. Design, Setting, and Participants This was a retrospective study across 14 databases (6 administrative claims and 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non–GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to December 31, 2023. The incidence proportion and rate of NAION were calculated. Association between semaglutide and NAION was assessed using 2 approaches: an active-comparator cohort design comparing new users of semaglutide with those taking other GLP-1RAs and non–GLP-1RA drugs, and a self-controlled case-series (SCCS) analysis to compare individuals’ risks during exposure and nonexposure periods for each drug. The cohort design used propensity score–adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). Network-wide HR and IRR estimates were generated using a random-effects meta-analysis model. Exposures GLP-1RA and non–GLP-1RAs. Main Outcomes and Measures NAION under 2 alternative definitions based on diagnosis codes: one more inclusive and sensitive, the other more restrictive and specific. Results The study included 37.1 million individuals with T2D, including 810 390 new semaglutide users. Of the 43 620 new users of semaglutide in the Optum’s deidentified Clinformatics Data Mart Database, 24 473 (56%) were aged 50 to 69 years, and 26 699 (61%) were female. The incidence rate of NAION was 14.5 per 100 000 person-years among semaglutide users. The HR for NAION among new users of semaglutide was not different compared with that of the non–GLP-1RAs using the sensitive NAION definition—empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P = .12), sitagliptin (HR, 1.30; 95% CI, 0.56-3.01; P = .27), and glipizide (HR, 1.23; 95% CI, 0.66-2.28; P = .25). The risk was higher only compared with patients taking empagliflozin (HR, 2.27; 95% CI, 1.16-4.46; P = .02) using the specific definition. SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P &amp;lt; .001). Conclusions and Relevance Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association.